Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
- 2 October 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (3) , 905-927
Abstract
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are proglucagon derived peptides that are released from gut endocrine cells in response to nutrient intake. These molecules are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limit their use as therapeutic agents. The recent emergence of three-dimensional structures of G protein coupled receptors (GPCR) such as GLP-1R and glucagon receptor has helped to drive the rational design of innovative peptide molecules that hold promise as novel peptide therapeutics. One emerging area is the discovery of multifunctional molecules that act at two or more pharmacological systems to enhance therapeutic efficacy. In addition, drug discovery efforts are also focusing on strategies to improve patient convenience through alternative routes of peptide delivery. These novel strategies highlight the broad utility of peptide-based therapeutics in human disease settings where unmet needs still exist.Keywords
This publication has 149 references indexed in Scilit:
- Molecular basis for negative regulation of the glucagon receptorProceedings of the National Academy of Sciences of the United States of America, 2012
- An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomersJournal of Clinical Investigation, 2012
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and PioglitazoneThe Scientific World Journal, 2012
- The metabolic actions of glucagon revisitedNature Reviews Endocrinology, 2010
- The incidence of bariatric surgery has plateaued in the U.S.The American Journal of Surgery, 2010
- Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 ReceptorJournal of Biological Chemistry, 2010
- Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic SteatohepatitisHepatology, 2009
- Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based managementTherapeutic Advances in Medical Oncology, 2009
- Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityGut, 2009
- Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptorProceedings of the National Academy of Sciences, 2007